Certuity’s CytomX Therapeutics CTMX Stock Holding History

Certuity’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,000	Closed	-$22K	–	220
2022 Q3	$22K	Buy	+15,000	New	+$23.1K	0.01%	194

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Certuity's CTMX Position: Q4 2022 in Review

Certuity sold out of CytomX Therapeutics (CTMX) in Q4 2022, closing a stake of 15,000 shares — an estimated $22K sold.

Certuity first reported a position in CTMX in Q3 2022 and held it in 1 quarter. The position peaked at $22K in Q3 2022. 81 funds tracked by Wall St. Rank hold CTMX as of Q4 2022.

Certuity reported no remaining CytomX Therapeutics position as of Q4 2022 after selling out during the quarter.
Certuity sold 15,000 CytomX Therapeutics shares in Q4 2022, an estimated $22K.
Certuity first reported a position in CytomX Therapeutics in Q3 2022 and held it in 1 quarter.
Certuity's CytomX Therapeutics position peaked at $22K in Q3 2022.
81 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2022.

Based on Certuity's 13F filing for Q4 2022, filed 13 Feb 2023.